Dabrafenib

Dabrafenib
Clinical data
Trade names	Tafinlar
Other names	GSK-2118436
AHFS/Drugs.com	Monograph
MedlinePlus	a613038
License data	US DailyMed: Dabrafenib;
Routes of; administration	By mouth
ATC code	L01EC02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide;
CAS Number	1195765-45-7;
PubChem CID	44462760;
DrugBank	DB08912;
ChemSpider	25948204;
UNII	QGP4HA4G1B;
KEGG	D10064;
ChEBI	CHEBI:75045;
ChEMBL	ChEMBL2028663;
PDB ligand	P06 (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID20152499 ;
ECHA InfoCard	100.215.965
Chemical and physical data
Formula	C23H20F3N5O2S2
Molar mass	519.56 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F;
	InChI InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29); Key:BFSMGDJOXZAERB-UHFFFAOYSA-N;

Dabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF.^[2] Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.

The most common side effects include papilloma (warts), headache, nausea, vomiting, hyperkeratosis (thickening and toughening of the skin), hair loss, rash, joint pain, fever and tiredness.^[3] When taken in combination with trametinib, the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash.^[3]

Dabrafenib was approved for medical use in the United States in May 2013,^[7] and in the European Union in August 2013.^[3]

^ "Product monograph brand safety updates". Health Canada. February 2024. Retrieved March 24, 2024.
^ ^a ^b "Tafinlar- dabrafenib capsule". DailyMed. U.S. National Library of Medicine. June 22, 2022. Archived from the original on January 27, 2023. Retrieved January 27, 2023.
^ ^a ^b ^c ^d Cite error: The named reference Tafinlar EPAR was invoked but never defined (see the help page).
^ Cite error: The named reference Finlee EPAR was invoked but never defined (see the help page).
^ "Tafinlar Product information". Union Register of medicinal products. August 29, 2013. Archived from the original on January 11, 2023. Retrieved December 11, 2023.
^ "Finlee Product information". Union Register of medicinal products. November 16, 2023. Archived from the original on November 26, 2023. Retrieved December 11, 2023.
^ Cite error: The named reference Tafinlar FDA approval package was invoked but never defined (see the help page).

[1] "Product monograph brand safety updates". Health Canada. February 2024. Retrieved March 24, 2024.

[Tafinlar_FDA_label-2] "Tafinlar- dabrafenib capsule". DailyMed. U.S. National Library of Medicine. June 22, 2022. Archived from the original on January 27, 2023. Retrieved January 27, 2023.

[Tafinlar_EPAR-3] Cite error: The named reference Tafinlar EPAR was invoked but never defined (see the help page).

[Finlee_EPAR-4] Cite error: The named reference Finlee EPAR was invoked but never defined (see the help page).

[5] "Tafinlar Product information". Union Register of medicinal products. August 29, 2013. Archived from the original on January 11, 2023. Retrieved December 11, 2023.

[6] "Finlee Product information". Union Register of medicinal products. November 16, 2023. Archived from the original on November 26, 2023. Retrieved December 11, 2023.

[Tafinlar_FDA_approval_package-7] Cite error: The named reference Tafinlar FDA approval package was invoked but never defined (see the help page).

[1]

[2]

[3]

[4]

[5]

[6]

[7]